<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-60557</identifier>
<setSpec>0213-005X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pharmacokinetics, interactions and mechanism of action of maraviroc</dc:title>
<dc:description xml:lang="en">Maraviroc (MVC, Celsentri®) is an allosteric and reversibleinhibitor of the CCR5 chemokine coreceptor. MVC is thefirst marketed CCR5 antagonist and the only oral entryinhibitor approved so far for the treatment of HIV infection.It has been approved for adults with previous antiretroviralexposure. MVC exclusively inhibits the replication of R5-tropic HIV-1 variants after binding to the transmembraneCCR5 receptor cavity. MVC is rapidly absorbed followingoral administration, and plasma Tmax is achieved within 0.5-4 hours after a 300 mg dose. Renal clearance isapproximately 10-12 L/h. MVC is a substrate of thecytochrome P450 isoenzyme 3A4; therefore doseadjustments are required when co-administrated with other drugs that induce or inhibit CYP3A4. In addition,MVC dose adjustments are advised in patients with renalfailure (CLcr &lt;80 ml/min) only if they receive CYP3A4inhibitors(AU)</dc:description>
<dc:creator>Poveda, Eva</dc:creator>
<dc:creator>Soriano, Vicente</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Maraviroc (MVC, Celsentri®) es un inhibidor alostérico yreversible del receptor de quimiocinas CCR5. MVC es elprimer antagonista de CCR5 comercializado y el únicoinhibidor de la entrada del VIH de administración oral. Seha aprobado para el tratamiento de pacientes VIH+ adultoscon exposición previa a otros antirretrovirales. Debeprescribirse en combinación con otros antirretrovirales.MVC inhibe específicamente la replicación de variantesvirales R5-trópicas mediante su unión al dominiotransmembrana del receptor CCR5. MVC se absorberápidamente tras su administración oral, y alcanza la Tmáxentre las 0,5 y 4 h después de una dosis oral de 300 mg. Elaclaramiento renal es aproximadamente de 10-12 l/h. MVCes sustrato del citrocromo P450 isoenzima 3A4, de modoque requiere ajuste de dosis cuando se coadministra conotros fármacos inductores o inhibidores del CYP3A4. Deigual forma, se recomienda un ajuste de la dosis de MVC enpacientes con insuficiencia renal (aclaración de creatinina &lt;80 ml/min) sólo si toman inhibidores del CYP3A4(AU)</dc:description>
<dc:source>Enferm Infecc Microbiol Clin;26(supl.11): 12-16, oct. 2008. tab, ilus</dc:source>
<dc:identifier>ibc-60557</dc:identifier>
<dc:title xml:lang="es">Maraviroc: farmacocinética, interaccionesy mecanismo de acción</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d36265^s22079</dc:subject>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d29416^s22021</dc:subject>
<dc:subject>^d50497^s22057</dc:subject>
<dc:subject>^d50572^s22079</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33498^s22006</dc:subject>
<dc:subject>^d4409</dc:subject>
<dc:type>article</dc:type>
<dc:date>200810</dc:date>
</metadata>
</record>
</ibecs-document>
